_256_384.jpg)
News | May 04, 2022
Eris Lifesciences acquires Oaknet Healthcare for Rs 650 crore
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world-leading life sciences hub
This facility will design & develop instruments, perform product reliability performance testing and verification
Peak Proteins has collaborated closely with Sygnature Discovery for several years and together the companies have supported a number of integrated drug discovery programmes
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
Access Healthcare for Medical Products (Access Healthcare) provides pharmaceutical companies with innovative marketing and sales solutions in the MENA (Middle East & North Africa) region
Healthium Medtech, a company focused on products used in surgical, post-surgical and chronic care has ramped up its play in the global healthcare industry. In an interview with Thomas C. Thottathil, Editor, Indian Pharma Post, Anish Bafna, CEO and MD, Healthium Medtech outlines his plans
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
Subscribe To Our Newsletter & Stay Updated
